G92.05
Immune effector cell-associated neurotoxicity syndrome, grade 5
Clinical Classification Guidelines
Inclusion Terms
- ICANS, grade 5
Medical Intelligence & Overview
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) is a serious neurological complication that can occur after certain immunotherapies, particularly those involving immune effector cells like CAR T-cell therapy. When ICANS progresses to the most severe level, classified as grade 5, it indicates life-threatening neurological damage. This guide provides an overview of grade 5 ICANS, highlighting its causes, symptoms, diagnosis, and the importance of prompt medical attention.
Causes & Symptoms
Clinical Causes: Therapies involving immune effector cells, such as CAR T-cell therapy Severe immune response leading to widespread inflammation in the brain Overactivation of immune cells resulting in cytokine release syndrome (CRS), which can precipitate ICANS Preexisting neurological conditions exacerbating immune reactions in the nervous system
Key Symptoms: Profound altered mental status, including coma Loss of consciousness Seizures or status epilepticus Significant cerebral edema or swelling of the brain Severe headaches and neck stiffness Difficulty speaking or understanding speech Motor weakness or paralysis Visual disturbances or hallucinations Signs of increased intracranial pressure such as vomiting or papilledema
Diagnostic & Treatment
Diagnosis Path: Neurological examination assessing mental status, cranial nerves, motor and sensory functions Brain imaging studies, such as MRI or CT scans, to detect swelling or other abnormalities Electroencephalogram (EEG) to evaluate seizure activity Laboratory tests to rule out infections or other causes of neurological symptoms Assessment of recent immunotherapy treatments and other clinical history
Treatment Protocols: Admission to an intensive care unit (ICU) for close monitoring Administration of corticosteroids to reduce brain inflammation Use of anti-seizure medications in cases of seizures Supportive care, including mechanical ventilation if respiratory compromise occurs Management of intracranial pressure with medications or surgical intervention if necessary Treating underlying causes like cytokine release syndrome to stabilize immune response Multidisciplinary team involvement, including neurologists and intensivists, for personalized care
Clinical Advice & FAQs
Billing Guidance
Is G92.05 a billable ICD-10 code?
Yes, G92.05 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G92.05?
Clinical documentation must specify the nature of Immune effector cell-associated neurotoxicity syndrome, grade 5 and any associated comorbidities for accurate reporting.
Cite this Clinical Reference